Recent Updates
Recently added Catalysts
PRLD Positive Sentiment

A Phase 1 Study of PRT2527, a Selective CDK9 Inhibitor, as Monotherapy and in Combination With Zanubrutinib in Relapsed / Refractory Lymphoid Malignancies: Updated Analysis

Wednesday, June 18, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses an updated analysis of a Phase 1 study evaluating PRT2527, a selective CDK9 inhibitor, both as a standalone treatment and in combination with zanubrutinib for patients with relapsed or refractory lymphoid malignancies. The study aims to assess the safety and efficacy of these treatment options. Initial findings suggest a positive outlook for PRT2527 in this patient population.
Price reaction · baseline $0.9275 (2025-06-17 close) · hit pre-market · clean, no other PRLD news in the window
day 0 close
-7.2%
day 1 · peak
-7.2%
day 3
-5.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • PRT2527 shows promise as a selective CDK9 inhibitor.
  • The study includes both monotherapy and combination therapy approaches.
  • Potential for effective treatment in relapsed/refractory lymphoid malignancies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+217%
120-day peak, hindsight
Typical move
8.2%
average across 4 past catalysts
Cash runway
~29 mo
Minimal dilution risk
Lead asset
PRT1419
Phase 1 · Multiple Myeloma

Full Press Release Details

Wojciech Jurczak, Clementine Sarkozy, Katharine L. Lewis, Geoffrey Shouse, Eliza A. Hawkes, Won Seog Kim, Monica Tani, François Lemonnier, Sarit E. Assouline, Franck Morschhauser, Bruce D. Cheson, Catherine S. Diefenbach, Gareth P. Gregory, Talha Munir, Petra Langerbeins, Constantine S. Tam, Gerardo Musuraca, Craig A. Portell, Anastasios Stathis, Young Rok Do, Jennifer Xavier, Muhtarjan Osman, Siminder K. Atwal, Jane Huang, Pier Luigi Zinzani

Frequently Asked Questions

What is PRT2527?

PRT2527 is a selective CDK9 inhibitor being studied for treating lymphoid malignancies.

What types of malignancies is PRT2527 targeting?

PRT2527 targets relapsed or refractory lymphoid malignancies.

What is the purpose of the Phase 1 study?

The Phase 1 study aims to evaluate the safety and efficacy of PRT2527.

How is PRT2527 administered in the study?

PRT2527 is administered both as a monotherapy and in combination with zanubrutinib.

ShareAdd on Google
Tags: PRLD Viatris Investor Conferences Healthcare PRT2527 CDK9 inhibitor lymphoid malignancies zanubrutinib Phase 1 study
Last updated: Jun 18, 2025

Biotech snapshot

Cash runway
$152M liquidity · $5M/mo burn
~29 mo
Minimal dilution risk
Lead asset
PRT1419Phase 1
Multiple Myeloma →

Catalyst track record

+217%
best trade around PRLD's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PRLD.

See every catalyst's timing & PoA →